NCT03263936 2025-10-16
Epigenetic Reprogramming in Relapse/Refractory AML
Therapeutic Advances in Childhood Leukemia Consortium
Phase 1 Completed
Clinical Trials
7 trialsNCT01483690 2020-10-27
A Pilot Study of Decitabine and Vorinostat With Chemotherapy for Relapsed ALL
Therapeutic Advances in Childhood Leukemia Consortium
Phase 1/2 Terminated
NCT00948064 2020-02-24
Vorinostat in Combination With Azacitidine in Patients With Newly-Diagnosed Acute Myelogenous Leukemia (AML) or Myelodysplastic Syndrome (MDS)
M.D. Anderson Cancer Center
Phase 2 Completed
NCT00818649 2017-12-28
Bortezomib and Vorinostat in Treating Patients With High-Risk Myelodysplastic Syndrome or Acute Myeloid Leukemia
Masonic Cancer Center, University of Minnesota
Phase 2 Terminated
NCT00882206 2017-12-28
Pre-reinductive Decitabine and Vorinostat in Relapsed Lymphoblastic Lymphoma or Acute Lymphoblastic Leukemia
Masonic Cancer Center, University of Minnesota
Phase 2 Terminated
NCT00479232 2015-09-21
Phase I Trial of Vorinostat (MK-0683, SAHA) in Combination With Decitabine in Patients With AML or MDS (MK-0683-055 EXT1)
Merck Sharp & Dohme LLC
Phase 1 Completed
NCT00656617 2015-03-09
Phase II Study of Idarubicin, Cytarabine, and Vorinostat With High-Risk Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML)
M.D. Anderson Cancer Center
Phase 2 Completed